These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 19243210

  • 1. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.
    Lenox-Smith A, Greenstreet L, Burslem K, Knight C.
    Clin Drug Investig; 2009; 29(3):173-84. PubMed ID: 19243210
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ, Casciano J, Arikian S, Tarride JE, Gonzalez MA, Casciano R.
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
    Nordström G, Danchenko N, Despiegel N, Marteau F.
    Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
    [Abstract] [Full Text] [Related]

  • 6. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
    Wade AG, Toumi I, Hemels ME.
    Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
    Snedecor SJ, Botteman MF, Schaefer K, Sarocco P, Barry N, Pickard AS.
    J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation.
    Kongsakon R, Bunchapattanasakda C.
    J Med Assoc Thai; 2008 Jul; 91(7):1117-28. PubMed ID: 18839855
    [Abstract] [Full Text] [Related]

  • 14. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
    Sørensen J, Stage KB, Damsbo N, Le Lay A, Hemels ME.
    Nord J Psychiatry; 2007 Jul; 61(2):100-8. PubMed ID: 17454724
    [Abstract] [Full Text] [Related]

  • 15. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.
    Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N.
    Eur Arch Psychiatry Clin Neurosci; 2009 Apr; 259(3):172-85. PubMed ID: 19165525
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective.
    Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G.
    Eur J Health Econ; 2010 Feb; 11(1):35-44. PubMed ID: 19506926
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A budget-impact and cost-effectiveness model for second-line treatment of major depression.
    Malone DC.
    J Manag Care Pharm; 2007 Jul; 13(6 Suppl A):S8-18. PubMed ID: 17874482
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.